Sify.com » Topics » Biocon
Biocon News
Biocon Announces Positive Efficacy Data with its Novel Monoclonal Antibody Itolizumab in a Pivotal Psoriasis Study
Bengaluru, Karnataka, India and San Francisco, United States:Biocon, Asia's premier biotechnology Company today, announced positive results from its Double Blind, Placebo Controlled, Phase 3, TREAT-PLAQ Study with Itolizumab in chronic plaque psoriasis. Itolizumab, the first humanized anti CD-6 monoclonal antibody, successfully met the pre-specified primary endpoint of significant improvement in PASI-75
Bengaluru, Karnataka, India and San Francisco, United States:Biocon, Asia's premier biotechnology Company today, announced positive results from its Double Blind, Placebo Controlled, Phase 3, TREAT-PLAQ Study with Itolizumab in chronic plaque psoriasis. Itolizumab, the first humanized anti CD-6 monoclonal antibody, successfully met the pre-specified primary endpoint of significant improvement in PASI-75
Quote, unquote
Kiran Mazumdar Shaw of Biocon is not normally known for intemperate statements. So when she is quoted in the latest edition of the New Yorker magazine as calling Pranab Mukherjee a
Biocon in pact with US firm Pacific Biomarkers
Clinigene International, a subsidiary of Biocon, and Pacific Biomarkers, a Washington-based company, has announced a collaborative clinical research agreement to address the speciality biomarker and
Clinigene International, a subsidiary of Biocon, and Pacific Biomarkers, a Washington-based company, has announced a collaborative clinical research agreement to address the speciality biomarker and
Clinigene International Enters into Collaborative Clinical Research Services
Clinigene International Limited, a subsidiary of Biocon, Indiaâ€s largest Biotech Company, and Pacific Biomarkers Inc. (PBI), a Seattle, WA-based limited liability company announce a collaborative agreement to address the specialty biomarker and high-end clinical trial laboratory needs of the global pharmaceutical and biotechnology industry.
Clinigene International Limited, a subsidiary of Biocon, Indiaâ€s largest Biotech Company, and Pacific Biomarkers Inc. (PBI), a Seattle, WA-based limited liability company announce a collaborative agreement to address the specialty biomarker and high-end clinical trial laboratory needs of the global pharmaceutical and biotechnology industry.
Don't allow political differences hurt progress: Tata
Political differences should not be allowed to come in the way of India's progress, Tata Group Chairman Ratan Tata said, while expressing concerns over slowing down of the economy. Other corporate
Political differences should not be allowed to come in the way of India's progress, Tata Group Chairman Ratan Tata said, while expressing concerns over slowing down of the economy. Other corporate
Biocon against national pharmaceuticals policy
The proposed national pharmaceuticals policy that seeks to control the prices of drugs will only end up devaluing the country’s pharma sector, Biocon Limited said on Thursday.
The proposed national pharmaceuticals policy that seeks to control the prices of drugs will only end up devaluing the country’s pharma sector, Biocon Limited said on Thursday.
© Copyright Sify Technologies Ltd, 1998-2011. All rights reserved. India News Portal, Sify.com hosted at SifyHosting India's first Level 3 Internet Data Centre.
Site optimized for Internet Explorer 5.5 and above.
See Disclaimer |Privacy Policy &Parental Guidance on pornography |careers@sify |About Us |Feedback |Advertise
Site optimized for Internet Explorer 5.5 and above.
See Disclaimer |Privacy Policy &Parental Guidance on pornography |careers@sify |About Us |Feedback |Advertise